Xiaoyi Chen
Rutgers Cancer Institute of New Jersey
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Xiaoyi Chen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07867626 · Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AMLRutgers, The State University of New Jersey · not yet recruiting · Acute Myeloid Leukaemia (AML) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:37 UTC. The ranking covers the 200 most relevant of 22 PubMed records, and a shared surname and initials can bring in a namesake. All 22 on PubMed
- 73 citationsRCR 4.5
- Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center.Blood Cancer J · 202158 citationsRCR 2.9
- A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome.J Cancer Res Clin Oncol · 202328 citationsRCR 2.2
- Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.Biol Blood Marrow Transplant · 201424 citationsRCR 0.8
- 18 citationsRCR 0.6
- Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens.J Transl Med · 201816 citationsRCR 0.6
- Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.Front Med · 201915 citationsRCR 0.8
- Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.J Transl Med · 201915 citationsRCR 0.5
- Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China.Int J Hematol · 201114 citationsRCR 0.5
- 13 citationsRCR 0.5